Advertisement

Topics

Sorrento Therapeutics Subsidiary, Scilex, Raises $140 million in Non-Dilutive Royalty-Based Financing

11:47 EDT 10 Sep 2018 | Investing News Network

Sorrento Therapeutics (NASDAQ:SRNE) that its majority-owned subsidiary, Scilex Pharmaceuticals, closed a debt financing with leading global institutional investors for aggregate gross proceeds to Scilex of $140 million. As quoted in the press release: “This non-dilutive financing provides Scilex with the capital resources to successfully execute on the launch of ZTlido,” said Henry Ji, Chairman, President … Continued

The post Sorrento Therapeutics Subsidiary, Scilex, Raises $140 million in Non-Dilutive Royalty-Based Financing appeared first on Investing News Network.

Original Article: Sorrento Therapeutics Subsidiary, Scilex, Raises $140 million in Non-Dilutive Royalty-Based Financing

NEXT ARTICLE

More From BioPortfolio on "Sorrento Therapeutics Subsidiary, Scilex, Raises $140 million in Non-Dilutive Royalty-Based Financing"

Advertisement
Quick Search
Advertisement
Advertisement